The therapy’s dual-NMR agonism could help in managing pain. Credit: Zay Nyi Nyi/Shutterstock.

Tris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate-to-severe acute pain in individuals post-abdominoplasty surgery.

The findings highlight the therapy’s safety and ‘efficacy’ profile as a first-in-class pain therapy with dual-nociceptin/orphanin’ FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor (dual-NMR) agonism, aiming to provide substantial relief with minimised side effects risk and addiction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The randomised, placebo-controlled, double-blind trial’s primary endpoint was the reduction in pain intensity, measured by the Pain Numeric Rating Scale (NRS) Area Under the Curve for 44 hours post-surgery (AUC4-48).

A dosage of 400µg, administered one time a day for two days, achieved a statistically significant decrease in pain intensity compared to a placebo, with a ‘favourable’ safety profile.

Nausea was the most observed adverse event with no other therapy-related serious events reported.

Tris Pharma CEO and founder Ketan Mehta said: “We are excited by the results from the ALLEVIATE-1 trial demonstrating a strong level of pain relief.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The opioid crisis has highlighted the urgent need for pain management options that treat moderate-to-severe pain as effectively as opioids but do not carry similar risk of addiction and detrimental side effects.”

Cebranopadol’s dual-NMR agonism could help manage pain by balancing analgesic efficacy and safety.

The company anticipates sharing additional trial outcomes in the first quarter of this year. These will include findings from an intranasal human abuse potential study and ALLEVIATE-2, another Phase III trial post-bunionectomy, with a new drug application (NDA) submission anticipated later this year.

At the start of the second half, the company is planning to conduct studies related to the therapy for several indications of chronic pain.

Last August, Tris Pharma commenced two pivotal Phase III studies, ALLEVIATE-1 and ALLEVIATE-2, to assess the therapy.